Endotherapy for Painless Chronic Pancreatitis
Unknown statusNot applicableNCT05261997
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This is a prospective randomized controlled trial. . Patients will be divided into conservative or endoscopic group and fecal pancreatic elastase-1 (FE-1) is tested to evaluate pancreatic exocrine function. The effect of extracorporeal shock wave lithotripsy and endoscopic treatment on the progression of chronic pancreatitis in painless patients will be determined.
Study details
- Official title
- Effect of Endotherapy on the Progression of Chronic Pancreatitis in Painless Patients
- Conditions
- Pancreatitis, Chronic
- Exocrine Pancreatic Insufficiency
- Abdominal Pain
- Cholangiopancreatography, Endoscopic Retrograde
- Interventions
- Procedure: extracorporeal shock wave lithotripsy and endoscopic drainage of the main pancreatic duct
- Drug: pancreatic enzyme(Pancreatin Enteric-coated Capsules or Oryz-Aspergillus Enzyme and Pancreatin Table), antidiabetic medicine(Acarbose Tablets, Glucophage, Glimepirde Tablets)
- Sponsor
- Changhai Hospital
- Start date
- 2022-03
- Primary completion
- 2023-11
- Sex
- All
- Age range
- from 18 Years to 70 Years
- Results posted
- No results posted in this snapshot
- Countries
- China
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * diagnosed with chronic pancreatitis without pain attack related with chronic pancreatitis; * calcified stone in the cephalic or corporeal portion of the main pancreatic duct with upstream duct dilation; * no ERCP or ESWL carried out before admission; Exclusion Criteria: * suspected to have malignant tumors; * history of pancreatic surgery or gastrojejunostomy (Billroth II); * with end-stage disease; * pregnancy or lactation; * refuse to write informed consent
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05261997